2022 at a Glance Chairman’s Letter CEO’s Report Key Milestones Pipeline Review ESG Financial Reports 43 Kazia Theraputics Limited Annual Report 2022 STATEMENT OF CASH FLOWS For the year ended 30 June 2022 Consolidated 2022 2021 Note $ $ Cash flows from operating activities Receipts from customers* - 13,739,254 Payments to suppliers (inclusive of GST) (22,787,619) (23,868,218) R&D cash rebate - 1,018,448 Government grant 10,000 - Bad debt recovery 14,956 - Net cash used in operating activities 31 (22,762,663) (9,110,516) Cash flows from investing activities Payment of milestone relating to contingent consideration 16 (2,364,732) - Net cash used in investing activities (2,364,732) - Cash flows from financing activities Proceeds from issue of shares - net of issuance costs 18 3,726,187 28,108,848 Net cash from financing activities 3,726,187 28,108,848 Net increase/(decrease) in cash and cash equivalents (21,401,208) 18,998,332 Cash and cash equivalents at the beginning of the financial year 27,586,760 8,764,044 Effects of exchange rate changes on cash and cash equivalents 1,175,560 (175,616) Cash and cash equivalents at the end of the financial year 9 7,361,112 27,586,760 * Receipts from customers were subject to deduction of VAT and withholding tax at source The above statement of cash flows should be read in conjunction with the accompanying notes Our Collaborators
RkJQdWJsaXNoZXIy MjE2NDg3